secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001193125-25-109976
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics to cut 45% of workforce; CLO Mike Ouimette departs
----------------------------------------------------------------------

- Reduction impacts ~45% of current employees; expected to substantially complete by end of Q2 2025.
- Total severance and related benefits estimated at $3.6M, primarily one-time cash termination benefits.
- Mike Ouimette, Chief Legal and Compliance Officer and Corporate Secretary, terminated effective May 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/0001193125-25-109976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312525109976/d949809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-109976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer